TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HS disease duration of at least 3 months before screening.~* Willingness to avoid pregnancy or fathering children.~* Active HS in at least 2 distinct anatomical areas.~* Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period~Exclusion Criteria:~* Draining fistula count of \> 20 at screening or baseline.~* Women who are pregnant (or who are considering pregnancy) or lactating.~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.~* History of failure to treatment of inflammatory diseases with JAK inhibitors.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.~* Laboratory values outside of the protocol-defined ranges.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INCB054707 15 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
- INCB054707 45 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
- INCB054707 75 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
- Placebo followed by INCB054707 75 mg (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ≥ 18 years of age~* All subjects must have newly diagnosed, histologically proven adenocarcinoma of the rectum~* All subjects must have an abdominal/pelvis computed tomography (CT ) scan or magnetic resonance imaging (MRI) confirming no evidence of distant metastases~* Distal border of tumor \< 12 cm from anal verge~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2~* No prior treatment for LARC however prior treatments for other cancers are acceptable as long as they are considered curative~Exclusion Criteria:~* Subject is an unsuitable candidate for TME surgery~* Subject has received anticancer therapy~* Subject has received prior radiation therapy~* Subject has had major surgery within 28 days prior to the first dose of study drug~* History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- veliparib and capecitabine and radiation (Type: EXPERIMENTAL): Veliparib on days 1-7, capecitabine and radiation on days 1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suppression of HIV 1 RNA in People Living With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* living with HIV~Exclusion Criteria:~* report current suicidal or homicidal ideation;~* have a severe psychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Incentive Group (Type: EXPERIMENTAL): Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
- Usual Care Group (Type: OTHER): Usual Care Control participants will receive the standard HIV medical care offered in their clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females aged ≥18 years~2. Congestive Heart Failure (CHF) New York Heart Association (NYHA) class II-IV with 25%≤ Left Ventricular Ejection Fraction (LVEF) ≤40% (ECHO within last 6 months)~   * NT-proBNP ≥ 600 pg/mL OR~  * NT-proBNP ≥ 400 pg/mL and a hospitalization for heart failure within the last 12 months~3. Stable and optimized on an angiotensin-converting-enzyme inhibitor (ACEI) equivalent to enalapril ≥ 10 twice a day (BID) for at least 4 weeks~4. Stable and optimized on a beta-blocker for at least 4 weeks~5. Optimized dosing of aldosterone antagonist at stable dose for at least 4 weeks~Exclusion Criteria:~1. History of angioedema~2. estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m2 at screening~3. Serum potassium \> 5.2 mmol/L at screening~4. Symptomatic hypotension as defined by Investigator, systolic blood pressure (SBP) \< 100 mmHg at screening~5. Current acute decompensated heart failure~6. History of severe pulmonary disease~7. Active malignancy~8. Requirement for treatment with both angiotensin-converting-enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label Entresto (Type: OTHER): All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants and children with a clinical diagnosis of hyperinsulinism who are suspected to have focal disease and are surgical candidates for pancreatectomy~Exclusion Criteria:~* Pregnant or lactating females~* Any other major illness or condition that might substantially increase the risk associated with the subject's participation in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (18F-DOPA) PET/CT imaging (Type: EXPERIMENTAL): Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* Overactive bladder for at least 3 months~* 3 day- voiding diary~  * average urinary frequency ≥ 10 voids/24hrs~ * urgency ≥ 2 episodes/24hrs~* moderate to severe in the Indevus Urgency Severity Scale (IUSS)~Exclusion Criteria:~* clinically significant stress urinary incontinence~* polyuria of more than 3000 ml/24 hrs~* severe hepatic or renal diseases~* contraindications to the use of antimuscarinic drugs~* genitourinary conditions that could cause OAB symptoms such as urinary tract infection, genitourinary malignancy or interstitial cystitis~* uninvestigated hematuria~* clinically significant bladder outlet obstruction~* clinically significant pelvic organ prolapse~* being on a bladder-training program or having been on electrostimulation therapy two weeks before randomization or intention to start~* unstable dosages of drugs with anticholinergic side effects~* any other investigational drug taken up to 2 months prior to randomization~* pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine patients who meet IHS criteria for migraine with or without aura of both sexes~* 18-70 years~* 45-95 kg.~Exclusion Criteria:~* Any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week)~* Serious somatic or psychiatric disease~* Pregnancy~* Intake of daily medication (except oral contraceptives)~* Triptan non-responders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: ACTIVE_COMPARATOR): headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
- Placebo (Type: PLACEBO_COMPARATOR): headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years old, diagnosed with end-stage kidney disease~* Undergoing thrice-weekly chronic hemodialysis for more than 90 days~* Exhibit a WI-NRS score of 3 or higher~Exclusion Criteria:~* Ahistory of hemp allergy~* Pregnancy or breastfeeding~* Dermatologic diseases~* Adjustments to medications for controlling itch within the 14 days preceding the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- hemp group (Type: EXPERIMENTAL): They was assigned to apply the hemp-containing cream.
- Control group (Type: PLACEBO_COMPARATOR): They was assigned to apply the placebo cream.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frequent migraine (\>=15 headache days per month)~* \>=4 distinct headache episodes lasting \>=4 hours~* \>=50% of baseline headache days migraine/probable migraine days~Exclusion Criteria:~* Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype~* Any medical condition that puts the patient at increased risk with exposure to BOTOX~* Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache~* Use of prophylactic headache medication within 28 days prior to week -4~* Unremitting headache lasting continuously throughout the 4-week baseline period~* Known or suspected TMD~* Diagnosis of fibromyalgia~* Beck depression inventory score \>24 at week-4~* Psychiatric problems that may have interfered with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- botulinum toxin Type A (Type: EXPERIMENTAL): Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
- Placebo (saline) (Type: PLACEBO_COMPARATOR): Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laser Light Cues for Gait Freezing in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects or a designated proxy have given informed consent~* Subject has been diagnosed with idiopathic Parkinson's disease~* Subject is ambulatory. If a wheelchair is used part-time, it must be used for less than 50% of the time~* Positive assessment for Questionnaire Used to Identify Freezing of Gait in PD Patients at subject's best on~Exclusion Criteria:~* Presence of atypical features suggestive of MSA, PSP, ataxia, unexplained or prominent pyramidal signs, and/or autonomic dysfunction~* Subjects who are non-ambulatory more than 50% of the time~* Subjects who have had a history of syncope in the 6 months prior to screening~* Subjects with moderate or advanced dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 mo baseline (Type: ACTIVE_COMPARATOR): 1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
- 2 month baseline (Type: NO_INTERVENTION): Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged ≥0 years at time of diagnosis with Chagas' disease~* Diagnosis of Chagas' disease confirmed by parasitological and/or serological method(s) before start of antitrypanosomal treatment or during the course of this antitrypanosomal treatment cycle for the first episode recorded.~Exclusion Criteria:~* Treatment with antitrypanosomal agent(s) other than nifurtimox, including experimental investigational products for Chagas' disease or antitrypanosomal combination treatment~* Patients with known evidence of organ manifestation of chronic Chagas' disease, e.g.Chagas' disease-related cardiomyopathy/heart disease, Chagas' disease-related digestive disease at time of primary diagnosis.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: None): Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
- Reference (Type: None): Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients between the age of 50 and 75 years referred to the Forzani \& MacPhail Colorectal Cancer Screening Centre in Calgary, Alberta, Canada for colonoscopy will be considered for inclusion.~Exclusion Criteria:~* patients with acute coronary syndrome,~* congestive heart failure,~* unstable angina,~* known or suspected renal failure,~* ascites,~* megacolon,~* known or suspected bowel obstruction, or~* other comorbidities that may prevent colonoscopy will be excluded. Patients will also be excluded if they previously had partial or subtotal colectomy or if the colonoscopy is warranted for the evaluation of diarrhea.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PEG - 4 L (Type: EXPERIMENTAL): 4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
- Split Dose PEG (Type: ACTIVE_COMPARATOR): 4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion:~1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate~2. You must have been diagnosed with schizophrenia~3. You must be able to visit the doctor's office as scheduled for the next 7 months~Exclusion:~1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)~2. You are either pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete